Lateral flow immunoassay with upconverting nanoparticle‐based detection for indirect measurement of interferon response by the level of MxA

Juntunen, Etvi; Salminen, Teppo; Talha, Sheikh M.; Martiskainen, I.; Soukka, Tero; Pettersson, Kim; Waris, Matti

doi:10.1002/jmv.24689

Cited by 24 publications

(13 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, fluorescence signals are sensitive to intrinsic and extrinsic conditions, such as salinity, pH, solvation environment of the dye, and so on. Commonly used materials are silica [101], quantum dots [109] and carbon dots [91] and upconverting NPs (UCNPs) [102].…”

Section: Novel Modifications Of Paper-based Assaysmentioning

confidence: 99%

Designing Paper-Based Immunoassays for Biomedical Applications

Hristov

Rodriguez-Quijada

Gómez-Márquez

et al. 2019

Sensors

View full text Add to dashboard Cite

Paper-based sensors and assays have been highly attractive for numerous biological applications, including rapid diagnostics and assays for disease detection, food safety, and clinical care. In particular, the paper immunoassay has helped drive many applications in global health due to its low cost and simplicity of operation. This review is aimed at examining the fundamentals of the technology, as well as different implementations of paper-based assays and discuss novel strategies for improving their sensitivity, performance, or enabling new capabilities. These innovations can be categorized into using unique nanoparticle materials and structures for detection via different techniques, novel biological species for recognizing biomarkers, or innovative device design and/or architecture.

show abstract

Section: Novel Modifications Of Paper-based Assaysmentioning

confidence: 99%

Designing Paper-Based Immunoassays for Biomedical Applications

Hristov

Rodriguez-Quijada

Gómez-Márquez

et al. 2019

Sensors

View full text Add to dashboard Cite

show abstract

“…Therefore, alternative labels and readout techniques are being developed to improve the limit of detection (LOD) and the working range of the LFIA. In particular, various types of particles such as quantum dots, , upconversion nanoparticles, , SERS tags, − and many others have been employed. Recently, Zherdev and Dzantiev discussed in their excellent review the five main steps toward the minimal LODs of the LFIA and provided important information about the current LFIA status.…”

Section: Introductionmentioning

confidence: 99%

Quantifying the Numbers of Gold Nanoparticles in the Test Zone of Lateral Flow Immunoassay Strips

Khlebtsov

Tumskiy

Буров

et al. 2019

ACS Appl. Nano Mater.

116

View full text Add to dashboard Cite

Lateral flow immunoassay (LFIA) is a rapid and simple point-of-care method for the detection of various analytes. In the colorimetric sandwich format, the reaction outcome is a colored test zone line formed by Au nanoparticle (AuNP) conjugates captured by bound analyte molecules. Although nanoparticle design is crucial for the assay sensitivity, the correlation between the test zone brightness and the number and size of captured AuNPs has not been studied in detail. To fill this gap, we used an unprecedented set of 10 spherical and monodisperse AuNPs with diameters d ranging from 16 to 115 nm. The calculated optical properties are in excellent agreement with two-layered Mie theory for Au cores coated with 3 nm CTAC shells with a refractive index of 1.5. Different concentrations of AuNPs (ICP-MS and UV–vis measurements) were spotted onto a nitrocellulose LFIA membrane, and the color intensity of the spots was measured and analyzed with RGB and HSV color parameters. The minimal detected spot intensity was proportional to the surface nanoparticle density and the particle volume. The derived size dependence means that extinction rather than scattering is the main physical mechanism behind spot brightness. The limit of detection (LOD) in terms of the surface nanoparticle density scaled like the inverse third power of the particle size (more precisely, like ∼d –3.1) and was about 7 × 107 and 1.5 × 105 particles/mm2 for 16 and 115 nm AuNPs, respectively. We analyzed an ideal LFIA format, when one analyte molecule delivers just one AuNP to the test zone. In this case, the theoretical LODs were in the pg/mL range for a typical LFIA format with 0.1 mL of a 25 kDa analyte. In practice, these estimations could be increased by 2 orders of magnitude because of the larger ratio of analyte to captured AuNPs. This strongly reduced the assay sensitivity to the the ng/mL level. Although an ideal LFIA predicts a strong increase in the assay sensitivity with the AuNP size (scales like ∼d 3.1), this improvement could be compensated for in part by an increase in the number of ineffective analyte molecules bound to the AuNP surface (scales like ∼d 2).

show abstract

“…However, faster methods of measuring MxA are available. 16 Based on our findings, MxA may improve the diagnostic workup in suspected COVID‐19 patients in the ED. Implementing MxA point‐of‐care‐testing as regular laboratory measurement in the ED can speed up decisions on required patient isolation measures before SARS‐CoV‐2 RT‐PCR results are available.…”

Section: Discussionmentioning

confidence: 67%

“…The current method of measuring MxA levels in whole blood requires 2‐h incubation, reducing its potential for use in the ED. However, faster methods of measuring MxA are available 16 . Based on our findings, MxA may improve the diagnostic workup in suspected COVID‐19 patients in the ED.…”

Section: Discussionmentioning

confidence: 69%

Blood myxovirus resistance protein‐1 measurement in the diagnostic work‐up of suspected COVID‐19 infection in the emergency department

Tong‐Minh

Hooijdonk

Versnel

et al. 2022

Immunity Inflam & Disease

View full text Add to dashboard Cite

Introduction: Myxovirus resistance protein 1 (MxA) is a biomarker that is elevated in patients with viral infections. The goal of this study was to evaluate the diagnostic value of MxA in diagnosing COVID-19 infections in the emergency department (ED) patients. Methods: This was a single-center prospective observational cohort study including patients with a suspected COVID-19 infection. The primary outcome of this study was a confirmed COVID-19 infection by RT-PCR test. MxA was assessed using an enzyme immunoassay on whole blood and receiver operating chart and area under the curve (AUC) analysis was conducted. Sensitivity, specificity, negative predictive value, and positive predictive value of MxA on diagnosing COVID-19 at the optimal cut-off of MxA was determined. Results: In 2021, 100 patients were included. Of these patients, 77 patients had COVID-19 infection and 23 were non-COVID-19. Median MxA level was significantly higher (p < .001) in COVID-19 patients compared to non-COVID-19 patients, respectively 1933 and 0.1 ng/ml. The AUC of MxA on a confirmed COVID-19 infection was 0.941 (95% CI: 0.867-1.000). The optimal cut-off point of MxA was 252 ng/ml. At this cut-off point, the sensitivity of MxA on a confirmed COVID-19 infection was 94% (95% CI: 85%-98%) and the specificity was 91% (95% CI: 72%-99%). Conclusion: MxA accurately distinguishes COVID-19 infections from bacterial infections and noninfectious diagnoses in the ED in patients with a suspected COVID-19 infection. If the results can be validated, MxA could improve the diagnostic workup and patient flow in the ED.

show abstract

Lateral flow immunoassay with upconverting nanoparticle‐based detection for indirect measurement of interferon response by the level of MxA

Cited by 24 publications

References 36 publications

Designing Paper-Based Immunoassays for Biomedical Applications

Designing Paper-Based Immunoassays for Biomedical Applications

Quantifying the Numbers of Gold Nanoparticles in the Test Zone of Lateral Flow Immunoassay Strips

Blood myxovirus resistance protein‐1 measurement in the diagnostic work‐up of suspected COVID‐19 infection in the emergency department

Contact Info

Product

Resources

About